New Statins Cholesterol Guidelines Mean More Than Half of American Adults Could Be on Medication Soon

People used to talk about cholesterol in this way: get a lipid panel when you turn 40 and wait for the numbers to get high enough to worry about. That framework has just changed in a big way. The new starting point is now 30 years old, thanks to updated guidelines from the American Heart Association, the American College of Cardiology, and nine other medical societies that work together.

The numbers are very interesting. According to a study released in JAMA on July 20, 2026, the new guidelines would make statin therapy available to about 87.5 million Americans between the ages of 30 and 79, which is about 57% of the adult population. That’s about 21.5 million more people than the rules from 2018 covered. So you can understand what that means, that’s more people than live in Florida.

The growth wasn’t caused by a single policy choice. It happened because of four separate changes that worked together. The age range that was used to figure out risk went from 40 to 75 to 30 to 79. A person is now considered to be at high risk if they have a 10% chance of having a cardiovascular event in the next ten years, instead of a higher bar. People with certain health problems, like type 2 diabetes, HIV, and advanced chronic kidney disease, are now automatically told to take statins, even if they don’t have a standard risk score. Also, and this may be the most important change, the guidelines now look at the cardiovascular risk over 30 years for adults aged 30 to 59, instead of just 10 years like they used to.

Things get a little more complicated after that last change. If you look ahead 10 years, a 38-year-old with borderline LDL levels might look fine. In the short term, their age keeps them safe. However, cardiovascular disease doesn’t show up before it’s time. Plaques made of LDL cholesterol build up slowly inside the walls of arteries over many years. These plaques can eventually lead to a heart attack or stroke. The main question that the new rules ask is: why wait until the process is well under way? It’s possible that earlier action, even small amounts of statins, could change the long-term picture for millions of people who feel fine right now and have no reason to think otherwise.

Still, there is a difference that you should remember. Just because you can get statins doesn’t mean you have to get a prescription. The rules are meant to start a conversation, not end it. A 33-year-old with slightly high LDL and no history of heart disease in their family is in a very different position than a 58-year-old with diabetes and high blood pressure who hasn’t done anything about their cholesterol levels. For people with a moderate risk, it may make sense to focus on diet, exercise, and weight management first, before turning to medication. Others, like those whose LDL levels are above 190 mg/dL or who have diabetes or chronic kidney disease, have a much stronger reason to start treatment.

The people who are being treated have also changed. For people with lower risk, the goal is to keep LDL below 100 mg/dL. For people with a higher risk, the goal drops to less than 70 mg/dL, and in some cases it’s even lower. High-intensity statins, such as atorvastatin 40–80 mg or rosuvastatin 20–40 mg, can lower LDL by 50% or more. Moderate doses, on the other hand, aim for lower levels of 30–49%. These medicines have been used for a long time and have a lot of real-world data to back them up. Statins are one of the most studied drugs in modern medicine. Most people can handle them well, but muscle pain and a small rise in blood sugar are still side effects that should be watched for.

Also, an incredibly interesting new choice is becoming available. The FDA just recently approved enlicitide, which is sold under the brand name Lipfendra. It is a daily pill made by Merck that works by blocking the PCSK9 protein, which controls how the liver removes LDL from the blood. It was shown in clinical trials to cut LDL by as much as 60%. The price for a 30-day supply is $315, which is a lot less than other injectable PCSK9 inhibitors that cost $500 or more a month and are harder to stick with. Cardiologists are excited about Lipfendra, but it’s still not clear if it will change how doctors treat high-risk patients who haven’t responded well enough to statins alone.

It’s hard not to notice that all of this is happening at a certain time, when preventive medicine is trying to get diseases to start earlier instead of treating ones that are already there. The new statin guidelines are a version of that instinct applied to cardiovascular risk. It’s still not clear if primary care offices will be able to handle the large number of newly eligible patients who may start coming in with questions. Right now, the easiest first step is to know your numbers and ask your doctor to run the PREVENT calculator. Be interested in your lifetime risk, not just the next ten years, when you talk to your doctor about it.